Direkt zum Inhalt
Merck
  • Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs.

Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs.

Veterinary anaesthesia and analgesia (2018-06-13)
Ira J Kallio-Kujala, Marja R Raekallio, Juhana Honkavaara, Rachel C Bennett, Heta Turunen, Mika Scheinin, Heidi Hautajärvi, Outi Vainio
ZUSAMMENFASSUNG

We determined the possible effects of a peripherally acting α2-adrenoceptor antagonist, MK-467, on the absorption of intramuscularly (IM) coadministered medetomidine, butorphanol and midazolam. Randomized, experimental, blinded crossover study. Six healthy Beagle dogs. Two IM treatments were administered: 1) medetomidine hydrochloride (20 μg kg-1) + butorphanol (100 μg kg-1) + midazolam (200 μg kg-1; MBM) and 2) MBM + MK-467 hydrochloride (500 μg kg-1; MBM-MK), mixed in a syringe. Heart rate was recorded at regular intervals. Sedation was assessed with visual analog scales (0-100 mm). Drug concentrations in plasma were analyzed with liquid chromatography-tandem mass spectrometry, with chiral separation of dex- and levomedetomidine. Maximum drug concentrations in plasma (Cmax) and time to Cmax (Tmax) were determined. Paired t-tests, with Bonferroni correction when appropriate, were used for comparisons between the treatments. Data from five dogs were analyzed. Heart rate was significantly higher from 20 to 90 minutes after MBM-MK. The Tmax values for midazolam and levomedetomidine (mean ± standard deviation) were approximately halved with coadministration of MK-467, from 23 ± 9 to 11 ± 6 minutes (p = 0.049) for midazolam and from 32 ± 15 to 18 ± 6 minutes for levomedetomidine (p = 0.036), respectively. MK-467 accelerated the absorption of IM coadministered drugs. This is clinically relevant as it may hasten the onset of peak sedative effects.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
4,5-Diphenylimidazol, 98%